Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
=== Legal issues === On April 14, 2013, Hart was charged on suspicion of drunk driving after his vehicle nearly collided with a tanker truck on a Southern California freeway. He failed a field sobriety test and was booked for misdemeanor driving under the influence. On August 5, he was sentenced to three years of probation after pleading no contest to one count of driving under the influence of alcohol.
The treatment at that time, endorsed by the leading German ophthalmologist Albrecht von Graefe, was an attempt to physically reshape the cornea by chemical cauterization with a silver nitrate solution and application of a miosis-causing agent with a pressure dressing. In 1888, the treatment of keratoconus became one of the first practical applications of the then newly invented contact lens, when the French physician Eugène Kalt manufactured a glass scleral shell that improved vision by compressing the cornea into a more regular shape. Since the start of the 20th century, research on keratoconus has both improved understanding of the disease and greatly expanded the range of treatment options. The first successful corneal transplantation to treat keratoconus was done in 1936 by Ramón Castroviejo.
=== Type 1 diabetes === Type 1 diabetes mellitus, also known as insulin-dependent diabetes, is believed to be caused by an auto-immune mediated destruction of the insulin-producing beta cells in the body. The process of beta-cell destruction begins with insulitis activating antigen-presenting cells (APCs). APCs then trigger activation of CD4+ helper-T cells and chemokines/cytokines release. Then, the cytokines activate CD8+ cytotoxic–T cells which leads to beta-cell destruction. The destruction of these cells reduces the body's ability to respond to glucose levels in the body, therefore making it nearly impossible to properly regulate glucose and glucagon levels in the bloodstream. The body destroys 70–80% of beta cells, leaving only 20–30% of functioning cells. This can cause the patient to experience hyperglycemia, which leads to other adverse short-term and long-term conditions. The symptoms of diabetes can potentially be controlled with methods such as regular doses of insulin and sustaining a proper diet. However, these methods can be tedious and cumbersome to continuously perform on a daily basis.
=== Contestants === 1st - Melanie Bjork-Jensen, Self-taught baker from West Jordan, Utah 2nd/3rd/4th - Alan Arras, Pastry Sous Chef from Orlando, Florida 2nd/3rd/4th - Cory Jones, Bakery Owner from Unadilla, Georgia 2nd/3rd/4th - Oksana Shchelgachova, Pastry Chef and Owner of Pastry Boutique from Highlands, North Carolina 5th - Camille La Caer, Pastry Chef from Buffalo, New York 6th - Jake Hagen, Pastry Chef from Granada Hills, California 7/8th - Gonzuela Bastarache, Home Baker from Moncton, New Brunswick, Canada 7/8th - Megan Carroll, Food Photographer from Minneapolis, Minnesota 9th - Nina Charles, Cake Artist and Bakery Owner from Carencro, Louisiana 10th - Justin Giordano, Cake Artist from New York City, New York
Sources: en.wikipedia.org
== Career == In 1992, Ülgen joined the faculty at Boğaziçi University as in instructor in the department of chemical engineering. She was promoted to assistant professor in 1994, associate professor in 1996, and professor in 2002. She served as head of the chemical engineering department from 2009 to 2011. Ülgen served as associate dean of the faculty of engineering from 2012 to December 2015. Ülgen researches pharmacophore modelling to identify pharmacological chaperones to treat infectious diseases, genetic diseases, and cancer. She uses a systems biology approach to investigate the reconstruction of signaling networks in yeast, worms, and humans. She also researches protein purification, computational physiology, and metabolic pathway engineering.
electron electric dipole moment (de) An intrinsic property of an electron such that its potential energy is linearly related to the strength of its electric field; a measure of the distribution of an electron's negative charge within the electric field it creates. See also electric dipole moment.
25 June – Astronomers report the discovery and confirmation of two unusually low-density exoplanets, TOI-791 b and TOI-791 c, orbiting the star TOI-791 about 1,113 light-years from Earth. Detected using NASA's Transiting Exoplanet Survey Satellite, the Jupiter-sized "super-puff" planets have densities of 0.038 and 0.047 g/cm3, respectively, making them among the lowest-density giant planets known and the largest planets yet found with densities below 0.05 g/cm3. 29 June – Palaeontologists identify a fossil vertebra collected on James Ross Island in 1985 as the earliest-known dinosaur bone collected in Antarctica. The specimen, stored for 40 years in the British Antarctic Survey collections, is confirmed to be a tail bone from a titanosaur, a group of long-necked sauropod dinosaurs. The animal is estimated to have lived about 82 million years ago, during the Late Cretaceous, when Antarctica was covered in forest. 30 June – Astronomers report a revised orbit and mass for the nearby habitable zone super-Earth GJ 3378 b. Combining radial velocity data from the Habitable-zone Planet Finder, NEID, CARMENES and SPIRou spectrometers, the team finds that the planet has an orbital period of 21.45 days and a minimum mass of 2.3 Earth masses, rather than earlier estimates of 24.73 days and 5.26 Earth masses. The revision leaves the planet within the conservative liquid-water habitable zone of its red dwarf host star, increases the likelihood that it has a terrestrial composition, and suggests that it may have retained an atmosphere despite high X-ray and ultraviolet exposure.
== Optical excitation and ionization schemes == Optical ionization schemes are developed to produce element-selective ion source for various elements. Most of the elements of the periodic table have been resonantly ionized by using one of five major optical routes based on the principle of RIMS. The routes were formed by the absorption of two or three photons to achieve excitation and ionization and are provided on the basis of optically possible transitions between atomic levels in a process called the bound-bound transition. For an atom of the element to be promoted to a bound-continuum, the energies emitted from the photons must be within the energy range of the selected tunable lasers. Also, the ionization energy of the last emitted photon must exceed that of the atom. The optical ionization schemes are denoted by the amount of photons necessary to make the ion pair. For the first two Schemes 1 and 2, two photons (and processes) are involved. One photon excites the atom from the ground state to an intermediate state while the second photon ionizes the atom. In Schemes 3 and 4, three photons (and processes) are involved. The first two distinct photons create consecutive bound-bound transitions within the selected atom while the third photon is absorbed for ionization. Scheme 5 is a three-photon two-intermediate-level photoionization process. After the first two photons have been absorbed by the optical energy, the third photon achieves ionization. The RIS process can be used to ionize all elements on the periodic table, except helium and neon, using available lasers.
==== Cash-and-carry wholesale ==== A "cash-and-carry" operator sells from a warehouse-style site where business customers generally pay at purchase and transport goods themselves. This model is common for small retailers and food service buyers in many countries.
Sources: en.wikipedia.org
The material to be dried is placed on a conveyor belt made of an infrared-transparent plastic, such as Mylar. The conveyor belt covers a reservoir of heated water. Where moist material contacts the Mylar film, an 'infrared window' is created. This allows infrared light to pass from the hot water to the moist material. Since the window requires moisture, it closes as the material dries, limiting the temperature to about 75°C. RWD boasts the use of three modes of heat transfer (convection in the water, conduction through the conveyor belt and radiation through the Mylar).
== Further reading == Bolsmann, Chris (1 November 2021). "'Playing With Apartheid': Irish and South African Rugby, 1964–19891". Sport History Review. 52 (2): 262–278. doi:10.1123/shr.2020-0027. S2CID 235043351. Booth, Douglas (1 July 2003). "Hitting Apartheid for Six? The Politics of the South African Sports Boycott". Journal of Contemporary History. 38 (3): 477–493. doi:10.1177/0022009403038003008. S2CID 145730533. Booth, Douglas (2013). "Recapturing the Moment? Global Rugby, Economics and the Politics of Nation in Post-Apartheid South Africa". In Chandler, Timothy J.L.; Nauright, John (eds.). Making the Rugby World. pp. 181–200. doi:10.4324/9781315036984. ISBN 978-1-135-22722-7. Nixon, Rob (1992). "Apartheid on the Run: The South African Sports Boycott". Transition (58): 68–88. doi:10.2307/2934968. JSTOR 2934968. Snyders, Hendrik (3 July 2018). "'An Outrage, Not Athletics': Apartheid and South African–United States Rugby Relations, 1976–1990". The International Journal of the History of Sport. 35 (10): 1029–1059. doi:10.1080/09523367.2019.1576636. S2CID 150831234. Snyders, Hendrik (2022). "Rugby, reconciliation, and post-apartheid public memory". Sport in Museums. pp. 80–91. doi:10.4324/9781351117944-6. ISBN 978-1-351-11794-4.
subunit A single unit of a multi-unit compound or molecular aggregate; e.g. a monomer from which a larger polymer is composed (as with nucleotides in nucleic acids), or an individual polypeptide chain in a multi-chain protein, or an entire protein which participates alongside other proteins as part of a protein complex.
LEDs have many advantages over incandescent light sources, including lower power consumption, reduced waste heat, a longer lifetime, improved physical robustness, smaller sizes, and faster switching. In exchange for these generally favorable attributes, disadvantages of LEDs include electrical limitations to low voltage and generally to DC (not AC) power, the inability to provide steady illumination from a pulsing DC or an AC electrical supply source, and a lesser maximum operating temperature and storage temperature. LEDs are transducers of electricity into light.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.